XORTX Therapeutics Inc., a pharmaceutical therapeutics company that is focusing on the development of the innovative therapies for the purpose of treating the progressive kidney disease announced that, it has submitted a clinical trial application (CTA) along with the Health Canada for a study of XRX-OXY-101 bridging pharmacokinetics.
The XRX-OXY-101 Bridging Pharmacokinetics Study has been designed with the three very important objectives including to determine which of the novel formulations of XORTX has been resulting in the best circulating oxypurinol concentrations, along with the effect of the food on the bioavailability of the particular formulation and the safety and pharmacokinetic of the multiple doses of the selected formulation.
Additionally, the study is also going to be providing the data for supporting the future New Drug Application marketing submissions to the Food and Drug Administration (FDA) of the United States and also the European Medicines Agency.
Dr. Allen Davidoff said that, the company ‘XORTX’ has been pleased for having made this step of regulatory filing for the purpose of initiating the launch of the XRX-OXY101 bridging pharmacokinetic study.
He also said that, in a duration of several months, this study has been an very important first clinical step in the company’s clinical and regulatory plans for the year 2022 and it is also going to be supporting the XRx-008 program for the ADPKD and also the planned ohase 3 registration trial.
This clinical trial, that is initiated in Canada is going to be providing an important information for being used for the development of the XRx-008 through the market approval process of the US FDA.
Editor/Content Writer
After discussions with the government, Premier League clubs have agreed to stop sponsoring their front…
Analysts reported that Novatek, a Russian natural gas producer, acquired Shell's stake in the Sakhalin-2…
The electric drivetrain of the next generation for Volkswagen's "ID" has been unveiled. Family EV.…
According to research, global egg prices are expected to remain at an all-time high until…
Ohme becomes Audi's Official UK Smart Charger Partner Ohme has been selected as Audi's new…
GM Ventures has signed a strategic agreement to develop EnergyX's lithium extraction and refinery technology,…